The relationship between clinicopathologic diagnosis and 123
Introduction
Dementia with Lewy bodies (DLB) is the second most common dementia type following Alzheimer's disease, accounting for 4.2% of all dementia cases in the population. 1 In our population-based study of residents of Olmsted County, Minnesota, the incidence rate of DLB was estimated at 3.5 per 100,000 person-years, which significantly increased with age. 2 Ante-mortem diagnostic accuracy of DLB is important for clinical management and disease-specific pharmacologic trials. The utility of 123 I-2b-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl) nortropane ( 123 I-FP-CIT) single-photon emission computed tomography (SPECT) in differentiating DLB from other dementia types has been evaluated. 3 Decreased striatal dopamine transporter uptake of 123 I-FP-CIT in This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
DLB is thought to reflect nigrostriatal degeneration in Lewy body disease (LBD). 4 In a multicenter phase III trial, abnormal 123 I-FP-CIT SPECT findings had 77.7% sensitivity and 90.4% specificity for distinguishing probable DLB from other dementias. 3 Given the high sensitivity and specificity of 123 I-FP-CIT SPECT for the diagnosis of DLB when combined with other clinical features, the revised consensus criteria for the clinical diagnosis of DLB include 123 I-FP-CIT SPECT as an indicative biomarker of DLB. 5 Limited studies have validated 123 I-FP-CIT SPECT findings in DLB with neuropathologic confirmation. [6] [7] [8] Decreased 123 I-FP-CIT binding in putamen measured semiquantitatively showed 88% sensitivity and 100% specificity for predicting LBD pathology at autopsy. 6 Abnormal 123 I-FP-CIT SPECT on visual rating was associated with LBD pathology with 80% sensitivity and 92% specificity. 8 Although high diagnostic accuracy of 123 I-FP-CIT SPECT for DLB/LBD was seen in these studies, the findings were based only on European patients with dementia. Here, we assess the clinical, pathologic, and 123 I-FP-CIT SPECT correlations in patients with dementia from one center in the United States.
Methods
Mayo Alzheimer's Disease Research Center (ADRC) participants who were diagnosed with a clinical dementia syndrome, underwent 123 I-FP-CIT SPECT imaging (performed as part of an ongoing ADRC imaging biomarker study in neurodegenerative conditions), and had neuropathologic evaluation at autopsy were included in the study. These patients had been followed longitudinally until death or until they were no longer able to participate in the research program between August 2003 and May 2016. Consensus clinical diagnosis of a dementia type, including Alzheimer's disease dementia (ADem), 9,10 DLB, 5,11 primary progressive aphasia (PPA)/frontotemporal lobar degeneration (FTLD), 12, 13 and corticobasal syndrome (CBS) 14, 15 was made based on previously published criteria. Rapid eye movement (REM) sleep behavior disorder (RBD) was diagnosed based on clinical +/À polysomnographic features. 16 123 I-FP-CIT SPECT (DaTscan, GE Healthcare, Chicago, IL) was performed 1-59 months prior to death according to previously published protocol.
17 123 I-FP-CIT SPECT findings were interpreted by radiologists in a blinded manner, and were considered abnormal if there was unequivocally reduced uptake in one or both putamen based on visual inspection. A mean putamen to occipital ratio (mPOR) was calculated for each patient by placing regions of interest over the right and left putamen and ipsilateral occipital cortical tissue and averaging the right and left putamen to occipital ratios. The calculation of mPOR was blinded with respect to the visual rating results as well as the clinical and pathologic diagnoses.
Neuropathologic diagnosis was made using previously published neuropathologic criteria, including Braak stages, 18, 19 I-FP-CIT SPECT findings between pathologically confirmed LBD and non-LBD cases were made using two-sided Wilcoxon rank-sum test due to non-normal distribution of the variable with a P < 0.05 being considered statistically significant. Statistical analysis was performed using JMP, version 10.0 (SAS Institute Inc, Cary, NC).
This study was approved by the Mayo IRB. Informed consent was obtained from the patients and/or their proxies.
Results
Eighteen patients met the inclusion criteria, of whom 12 had pathologic confirmation of LBD. The demographic, clinical, pathologic, and 123 I-FP-CIT SPECT characteristics of these patients are summarized in the Table 1 . The median age of onset of cognitive decline was 65.5 years (interquartile range [IQR] 59.5-71.0). These patients were longitudinally followed up for a median duration of 5 years (IQR 2-8). The patients with clinical diagnosis of AD predominantly presented with amnestic features, with impairment in other nonmemory domains. All DLB patients met criteria for probable DLB based on the third and fourth consensus criteria 5, 11 (i.e., all patients had at least two of the core clinical features, but 123 I-FP-CIT SPECT was not used for diagnosis). Patients who were diagnosed with DLB exhibited visuospatial and executive dysfunction in addition to memory impairment. Most of the DLB patients (11 of 12) had concurrent or subsequent development of parkinsonism and/or visual hallucinations. All patients with DLB were also diagnosed with polysomnography-confirmed RBD (10 of 12) or probable RBD (pRBD, 2 of 12) based on a strong history of dream enactment behavior. In most cases, RBD preceded the onset of cognitive decline in DLB by a median duration of 11 years (IQR 3.8-16.3). One patient with clinical diagnosis of ADem (Case 1) had a history consistent with probable RBD, although polysomnography demonstrated equivocal findings. Another patient with ADem (Case 4) had polysomnographic evidence of REM sleep without atonia in the absence of any clinical history of dream enactment behavior. Both of these patients were taking antidepressants at the time of polysomnography. Two patients (Cases 3 and 16) showed clinical features of both DLB and ADem, and were diagnosed as mixed DLB and ADem. Asymmetric limb apraxia, rigidity, and myoclonus were seen in the patient with CBS in addition to cognitive symptoms. One patient (Case 6) presented with prominent language dysfunction characterized by dysnomia, impaired object knowledge, and variable performance on repetition and comprehension measures, and he was diagnosed with PPA. 13 The patients came to autopsy at a median age of 75. I-2b-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl) nortropane; M, male; mPOR, mean putamen to occipital ratio; PA, pathologic aging; PPA, primary progressive aphasia; pRBD, probable rapid eye movement sleep behavior disorder; RBD, polysomnography-confirmed rapid eye movement sleep behavior disorder; SPECT, single-photon emission computed tomography; TDP, TAR DNA-binding protein 43. 
Discussion
In this study, reduced striatal uptake of 123 I-FP-CIT on visual rating was highly predictive of underlying LBD pathology in patients with dementia. Furthermore, semiquantitative analysis of 123 I-FP-CIT SPECT revealed that a reduction in mPOR was strongly associated with LBD. These findings are consistent with the results of previous European studies (Table 2) , [6] [7] [8] and support the utility of AD, Alzheimer's disease; ADem, Alzheimer's disease dementia; c, clinical diagnosis; CBS, corticobasal syndrome; DLB, dementia with Lewy bodies; FTLD, frontotemporal lobar degeneration; LBD, Lewy body disease; mPOR, mean putamen to occipital ratio; p, pathologic diagnosis; PPA, primary progressive aphasia sufficient to make a diagnosis of DLB, and should be used in conjunction with clinical features for the diagnosis of DLB.
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In this series, the results from visual inspection of 123 I-FP-CIT SPECT were mostly in agreement with mPOR. When discrepancy between visual rating and mPOR was present (Cases 5 and 18), mPOR appeared to be more consistent with the neuropathological findings. A potential limitation of visual rating in this study was the lack of assessment of interrater reliability as each 123 I-FP-CIT SPECT was read by a single radiologist. However, evaluating the diagnostic utility of 123 I-FP-CIT SPECT based on single radiologist interpretation is still meaningful as it mimics common clinical practice. Determining the superiority of semiquantitative analysis of 123 I-FP-CIT SPECT over visual rating was not possible in this study as the lack of mPOR data in a sufficient number of neurologically normal controls made the determination of abnormal mPOR cut-off difficult. A study comparing the qualitative and quantitative analyses of 123 I-FP-CIT SPECT is underway.
Another potential limitation of the study was a relatively small sample size. However, autopsy validation of 123 I-FP-CIT SPECT for predicting LBD strengthens the study findings. In addition, the results of the study were consistent with the findings of larger European studies, including~10% of cases with LBD pathology with normal findings on 123 I-FP-CIT SPECT. [6] [7] [8] One would also predict neurodegenerative disorders associated with dementia plus striatonigral pathology such as progressive supranuclear palsy and corticobasal degeneration would have reduced uptake on 123 I-FP-CIT SPECT, but since none of our patients had such pathologies, the generalizability to the full spectrum of patients with dementia cannot be addressed in this series. Another limitation was that the patients were evaluated by behavioral neurologists and their 123 I-FP-CIT SPECT findings were interpreted by radiologists at a large tertiary referral center, which likely increased the clinical and imaging diagnostic accuracy. A larger prospective multicenter study assessing the diagnostic utility of 123 I-FP-CIT SPECT in DLB with neuropathologic validation would increase the generalizability of the present findings. 
